Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 35, Issue -, Pages 193-195Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2019.08.006
Keywords
Multiple sclerosis; Ankylosing spondylitis; Secukinumab; TNF inhibitors; Clinical report
Categories
Ask authors/readers for more resources
The therapeutic approach to CNS demyelination associated to ankylosing spondylitis is a complex issue due to the contraindication of TNF inhibitors in demyelinating diseases. Secukinumab, a human IgG1 kappa monoclonal antibody that binds and inhibits IL-17A, was recently approved for the treatment of ankylosing spondylitis. We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available